Sema3f Protects Against Subretinal Neovascularization In Vivo

Ye Sun; Raffael Liegl; Yan Gong; Anima Bühler; Bertan Cakir; Steven S. Meng; Samuel B. Burnim; Chi-Hsiu Liu; Tristan Reuer; Peipei Zhang; Johanna M. Walz; Franziska Ludwig; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Günther Schlunck; Lois E.H. Smith; Andreas Stahl

doi:10.1016/j.ebiom.2017.03.026

EBioMedicine (Apr 2017)

Sema3f Protects Against Subretinal Neovascularization In Vivo

Ye Sun,
Raffael Liegl,
Yan Gong,
Anima Bühler,
Bertan Cakir,
Steven S. Meng,
Samuel B. Burnim,
Chi-Hsiu Liu,
Tristan Reuer,
Peipei Zhang,
Johanna M. Walz,
Franziska Ludwig,
Clemens Lange,
Hansjürgen Agostini,
Daniel Böhringer,
Günther Schlunck,
Lois E.H. Smith,
Andreas Stahl

Affiliations

Ye Sun: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Raffael Liegl: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Yan Gong: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Anima Bühler: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Bertan Cakir: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Steven S. Meng: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Samuel B. Burnim: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Chi-Hsiu Liu: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Tristan Reuer: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Peipei Zhang: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Johanna M. Walz: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Franziska Ludwig: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Clemens Lange: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Hansjürgen Agostini: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Daniel Böhringer: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Günther Schlunck: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
Lois E.H. Smith: Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
Andreas Stahl: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Germany

DOI: https://doi.org/10.1016/j.ebiom.2017.03.026
Journal volume & issue: Vol. 18, no. C
pp. 281 – 287

Abstract

Read online

Pathological neovascularization of the outer retina is the hallmark of neovascular age-related macular degeneration (nAMD). Building on our previous observations that semaphorin 3F (Sema3f) is expressed in the outer retina and demonstrates anti-angiogenic potential, we have investigated whether Sema3f can be used to protect against subretinal neovascularization in two mouse models. Both in the very low-density lipid-receptor knockout (Vldlr−/−) model of spontaneous subretinal neovascularization as well as in the mouse model of laser-induced choroidal neovascularization (CNV), we found protective effects of Sema3f against the formation of pathologic neovascularization. In the Vldlr−/− model, AAV-induced overexpression of Sema3f reduced the size of pathologic neovascularization by 56%. In the laser-induced CNV model, intravitreally injected Sema3f reduced pathologic neovascularization by 30%. Combined, these results provide the first evidence from two distinct in vivo models for a use of Sema3f in protecting the outer retina against subretinal neovascularization.

Published in EBioMedicine

ISSN: 2352-3964 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General)
Website: http://www.journals.elsevier.com/ebiomedicine/

About the journal

Abstract

Keywords